Gemcitabine-based therapy versus non-gemcitabine-based therapy as neoadjuvant for liver transplant recipients with cholangiocarcinoma: An institution experience

A. Esmail; M. Abdelrahim; J. Xu; R.M. Ghobrial

doi:10.1016/j.annonc.2024.05.304

Gemcitabine-based therapy versus non-gemcitabine-based therapy as neoadjuvant for liver transplant recipients with cholangiocarcinoma: An institution experience

A. Esmail, M. Abdelrahim, J. Xu, R.M. Ghobrial

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S126
Journal	Annals of Oncology
Volume	35
DOIs	https://doi.org/10.1016/j.annonc.2024.05.304
State	Published - Jun 2024

Access to Document

10.1016/j.annonc.2024.05.304

Cite this

@article{f01b3da118484569bbafc967e06db889,

title = "Gemcitabine-based therapy versus non-gemcitabine-based therapy as neoadjuvant for liver transplant recipients with cholangiocarcinoma: An institution experience",

author = "A. Esmail and M. Abdelrahim and J. Xu and R.M. Ghobrial",

note = "doi: 10.1016/j.annonc.2024.05.304",

year = "2024",

month = jun,

doi = "10.1016/j.annonc.2024.05.304",

language = "English (US)",

volume = "35",

pages = "S126",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Gemcitabine-based therapy versus non-gemcitabine-based therapy as neoadjuvant for liver transplant recipients with cholangiocarcinoma: An institution experience

AU - Esmail, A.

AU - Abdelrahim, M.

AU - Xu, J.

AU - Ghobrial, R.M.

N1 - doi: 10.1016/j.annonc.2024.05.304

PY - 2024/6

Y1 - 2024/6

U2 - 10.1016/j.annonc.2024.05.304

DO - 10.1016/j.annonc.2024.05.304

M3 - Article

SN - 0923-7534

VL - 35

SP - S126

JO - Annals of Oncology

JF - Annals of Oncology

ER -